ATE487487T1 - Verwendung von verbindungen, die die ef-tu- nucleolin wechselwirkung vehindern, zur verhinderung oder behandlung von tularämie - Google Patents
Verwendung von verbindungen, die die ef-tu- nucleolin wechselwirkung vehindern, zur verhinderung oder behandlung von tularämieInfo
- Publication number
- ATE487487T1 ATE487487T1 AT07301337T AT07301337T ATE487487T1 AT E487487 T1 ATE487487 T1 AT E487487T1 AT 07301337 T AT07301337 T AT 07301337T AT 07301337 T AT07301337 T AT 07301337T AT E487487 T1 ATE487487 T1 AT E487487T1
- Authority
- AT
- Austria
- Prior art keywords
- nucleolin
- preventing
- interaction
- compounds
- prevent
- Prior art date
Links
- 208000034784 Tularaemia Diseases 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 230000003993 interaction Effects 0.000 title abstract 2
- 102000008153 Peptide Elongation Factor Tu Human genes 0.000 abstract 3
- 108010049977 Peptide Elongation Factor Tu Proteins 0.000 abstract 3
- 108010044762 nucleolin Proteins 0.000 abstract 3
- 241000589602 Francisella tularensis Species 0.000 abstract 2
- 102100021010 Nucleolin Human genes 0.000 abstract 2
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940118764 francisella tularensis Drugs 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0208—Specific bacteria not otherwise provided for
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/18—Testing for antimicrobial activity of a material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07301337A EP2033655B1 (de) | 2007-09-04 | 2007-09-04 | Verwendung von Verbindungen, die die EF-Tu-Nucleolin Wechselwirkung vehindern, zur Verhinderung oder Behandlung von Tularämie |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE487487T1 true ATE487487T1 (de) | 2010-11-15 |
Family
ID=39032196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07301337T ATE487487T1 (de) | 2007-09-04 | 2007-09-04 | Verwendung von verbindungen, die die ef-tu- nucleolin wechselwirkung vehindern, zur verhinderung oder behandlung von tularämie |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP2033655B1 (de) |
| AT (1) | ATE487487T1 (de) |
| DE (1) | DE602007010459D1 (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2900341B1 (fr) | 2006-04-27 | 2012-09-14 | Centre Nat Rech Scient | Utilisation de ligands synthetiques multivalents de la nucleoline de surface pour le traitement du cancer |
| CA2724818C (en) | 2008-05-22 | 2015-06-16 | Centre National De La Recherche Scientifique (Cnrs) | New optically pure compounds for improved therapeutic efficiency |
| CA2813646A1 (en) * | 2010-10-04 | 2012-04-12 | Robert Zimmer | Multivalent synthetic compounds as antibiotic treatment |
| WO2012139046A2 (en) * | 2011-04-06 | 2012-10-11 | Cornell University | Signal amplification methods for the imaging of protein synthesis and neurotransmitter transport |
| CN103196877B (zh) * | 2013-03-08 | 2015-06-03 | 刘小龙 | 基于均相时间分辨荧光的检测重金属含量的方法 |
| WO2022015240A1 (en) * | 2020-07-13 | 2022-01-20 | National University Of Singapore | Peptide adjuvant for its therapeutic applications in viral and tumour vaccine development and cancer immunotherapy and autoimmune disease diagnosis and treatments |
| CN118393149A (zh) * | 2024-04-23 | 2024-07-26 | 重庆医科大学附属永川医院(重庆市第二人民医院) | 核仁素在血流感染诊断试剂和治疗药物中的应用及试剂盒 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1839960A1 (ru) * | 1987-01-19 | 2006-06-20 | Научно-исследовательский институт эпидемиологии и микробиологии им.Н.Ф.Гамалеи АМН | Штамм бактерий francisella tularensis для приготовления живой вакцины против туляремийной инфекции |
| WO1998014587A1 (en) * | 1996-10-04 | 1998-04-09 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTEMENT OF HEAL TH AND HUMAN SERVICES | Inhibition of hiv replication using soluble tat peptide analogs |
| US7357928B2 (en) * | 2002-04-08 | 2008-04-15 | University Of Louisville Research Foundation, Inc. | Method for the diagnosis and prognosis of malignant diseases |
| GB0214942D0 (en) * | 2002-06-28 | 2002-08-07 | Secr Defence | Immunogenic proteins and DNA encoding these |
-
2007
- 2007-09-04 DE DE602007010459T patent/DE602007010459D1/de active Active
- 2007-09-04 AT AT07301337T patent/ATE487487T1/de not_active IP Right Cessation
- 2007-09-04 EP EP07301337A patent/EP2033655B1/de not_active Not-in-force
Also Published As
| Publication number | Publication date |
|---|---|
| EP2033655B1 (de) | 2010-11-10 |
| DE602007010459D1 (de) | 2010-12-23 |
| EP2033655A1 (de) | 2009-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124144T1 (el) | Συνθεσεις και μεθοδοι για θεραπεια εγκεφαλικου επεισοδιου σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης | |
| ATE487487T1 (de) | Verwendung von verbindungen, die die ef-tu- nucleolin wechselwirkung vehindern, zur verhinderung oder behandlung von tularämie | |
| TW200714283A (en) | Method and composition for treating peripheral vascular diseases | |
| CY1121162T1 (el) | M-csf-ειδικο μονοκλωνικο αντισωμα και χρησεις αυτου | |
| CY1113963T1 (el) | Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν ανταγωνιστες ακτιβινης-actriia και χρηση αυτων στην προληψη η' θεραπευτικη αγωγη πολλαπλου μυελωματος | |
| ATE547102T1 (de) | Carbolin-derivate zur behandlung von krebs | |
| ATE543910T1 (de) | Verfahren und materialien zur herstellung von simvastatin und verwandten verbindungen | |
| CY1118089T1 (el) | Συνθεση υγρου διαπιδυσης η οποια περιλαμβανει ουσιες αναστολης της κρυσταλλωσης | |
| ATE540702T1 (de) | Verfahren für die überprüfbare inaktivierung von pathogenen in einem biologischen fluid durch bestrahlung | |
| ATE471334T1 (de) | Phosphoramidatderivate von nukleosidverbindungen zur verwendung bei der behandlung von krebs | |
| CY1115566T1 (el) | Παραγωγα phenoxypyridinyl amide και η χρηση τους στην θεραπεια καταστασεων ασθενειας με την μεσολαβηση της pde4 | |
| EP2282737A4 (de) | Zusammensetzungen und verfahren zur behandlung von parodontalerkrankung mit clonidin, sulindac und/oder fluocinolon | |
| CY1114920T1 (el) | Φαρμακευτικη συνθεση που περιεχει λακοσαμιδη και λεβετιρακεταμη με συνεργιστικη αντισπασμωδικη δραση | |
| DE602004031134D1 (de) | Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa | |
| CY1113485T1 (el) | Ενωσεις γεφυρωμενης-πιπεριδινης τυπου υποκατεστημενης-κινοξαλινης και οι χρησεις εξ' αυτων | |
| BRPI0908635A8 (pt) | composto, composição farmacêutica e método de tratamento de câncer | |
| EA200970718A1 (ru) | Лиганд-модифицированные полиоксогидроксидные материалы с ионами металла, их применение и способы их получения | |
| DE602005019247D1 (de) | Verwendung von cyclodextrin zur behandlung und vorbeugung von entzündlichen bronchialerkrankungen | |
| DE502006007526D1 (de) | Antimikrobielles medizintechnisches produkt, verfahren zu seiner herstellung und verwendung | |
| BRPI0417108A (pt) | métodos de tratamento de rejeições de transplantes em pacientes | |
| DK2229946T3 (da) | Anvendelse af vækst-stimulerende protein KIAA1524 | |
| GB2473575B (en) | Diagnosis of autism | |
| MX2012001999A (es) | Uso de inhibidores nkg2d para tratar enfermedades cardiovasculares y metabolicas, tal como diabetes tipo 2. | |
| ATE454465T1 (de) | In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie | |
| ATE480265T1 (de) | Verwendung von zahnfleischfibroblasten zur behandlung von vaskulären zellen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |